NCT01175278

Brief Summary

The purpose of this study is to find out how balloon kyphoplasty (surgical repair of the patient's fracture using balloons and bone cement) compares to non-surgical treatment in reducing vertebral compression fractures while providing pain relief and improved function and quality of life.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2010

Shorter than P25 for not_applicable multiple-myeloma

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2010

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 3, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 4, 2010

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2011

Completed
Last Updated

January 12, 2012

Status Verified

January 1, 2012

Enrollment Period

10 months

First QC Date

August 3, 2010

Last Update Submit

January 11, 2012

Conditions

Keywords

vertebralcompressionfractureVCFkyphoplastyspine

Outcome Measures

Primary Outcomes (2)

  • Time to Vertebral Event

    Time to vertebral event (composite end point of pain progression, hospitalization for pain, and rescue vertebral augmentation or surgery or radiation therapy as related to an index fracture)

    Average of 12 months

  • Time to Pain Progression

    Time to pain progression defined as the time to the development of pain severity rated greater than 4 on the visual analog scale (VAS) as related to an index fracture

    Average of 12 months

Secondary Outcomes (7)

  • Rate of Vertebral Events

    12 months

  • Rate of Hospitalization

    12 months

  • Complications of Procedure

    Average of 12 months

  • Quality of Life Questionnaire Results

    Average of 12 months

  • Changes in Pulmonary Function

    Average of 12 months

  • +2 more secondary outcomes

Study Arms (3)

Observation Arm

NO INTERVENTION

Patients who are asymptomatic (no symptoms) will participate in the observational portion of the study.

Balloon Kypholasty

EXPERIMENTAL
Procedure: Vertebral Augmentation with Balloon Kyphoplasty

Control Arm

ACTIVE COMPARATOR

Non-surgical Management Treatment Group

Other: Non-surgical Treatment

Interventions

Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.

Balloon Kypholasty

Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).

Control Arm

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with multiple myeloma (active or smoldering) with mild back pain (Visual Analog Scale \[VAS\]) ≤ 4 or no back pain (VAS=0) on a stable analgesic regimen) related to vertebral compression fractures (at least one and up to 8 index fractures from T3 to L5) as seen on magnetic resonancy imaging (MRI), computed axial tomography (CT) scan or plain radiographs.
  • No major planned spine surgery for at least 6 months following enrollment.
  • No evidence of epidural disease or cord compromise on magnetic resonance imaging.
  • Life expectancy greater than 6 months.
  • Adequate myeloma systemic control (no evidence of active progressive disease). No planned change in chemotherapy regimen for 1 month prior and for at least 1 month following enrollment. Change in dose(s) permitted.
  • Adequate hematologic parameters (platelet count≥50,000/μL, and absolute neutrophil count ≥1,000). Platelet transfusions are permitted to increase platelet counts perioperatively.
  • Age greater than 21 years and able to understand and sign the informed consent document.

You may not qualify if:

  • Patients with significant comorbidities (aside from the index fracture or cancer) which would result in an unacceptable surgical risk or patients with contraindications to general or local anesthesia.
  • Patients with other primary tumors including primary bone tumors or solitary plasmacytoma at site of the index VCF.
  • VCF morphology deemed unsuitable for balloon kyphoplasty (vertebra planum).
  • Additional non-kyphoplasty surgical treatment is required for the index fracture.
  • Patients with uncontrolled pain related to the VCF (VAS\>4, or increasing opioid requirements), or with epidural disease on magnetic resonance imaging. Spinal cord compression , canal compromise and /or spinal instability requiring decompression.
  • Patients with a bleeding disorder which cannot be adequately managed perioperatively.
  • Patients with pain unrelated to the VCF according to the investigators.
  • Patients with estimated survival less than 6 months.
  • Known allergy to bone cement or all contrast media used in the treatment of study participants.
  • MRI contraindication (e.g., cerebral aneurysm clips, pacemaker, implanted biostimulators, cochlear implants, penile prosthesis).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Multiple MyelomaFractures, Bone

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System DiseasesWounds and Injuries

Study Officials

  • Frank Vrionis, M.D.

    H. Lee Moffitt Cancer Center and Research Institute

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 3, 2010

First Posted

August 4, 2010

Study Start

July 1, 2010

Primary Completion

May 1, 2011

Study Completion

May 1, 2011

Last Updated

January 12, 2012

Record last verified: 2012-01